Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

[1] Kagami T(2016)Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype Aliment Pharmacol Ther 43 1048-1059

[2] Sahara S(2011)Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]- J Pharmacol Exp Ther 339 412-420

[3] Ichikawa H(2015)-methylmethanamin e monofumarate (TAK-438) Clin Transl Gastroenterol. 6 e94-648

[4] Shin JM(2015)Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects Aliment Pharmacol Ther 41 636-541

[5] Inatomi N(2008)Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects Helicobacter. 13 532-8

[6] Munson K(2004)Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Basic Clin Pharmacol Toxicol 95 2-418

[7] Sakurai Y(2016) eradication: a meta-analysis Clin Pharmacokinet 55 409-1535

[8] Nishimura A(2016)CYP2C19 polymorphism and proton pump inhibitors Adv Ther. 33 1519-342

[9] Kennedy G(2002)The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations Clin Pharmacokinet 41 329-undefined

[10] Jenkins H(undefined)Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study undefined undefined undefined-undefined

[1] Kagami T(2016)Potent acid inhibition by vonoprazan in comparison with esomeprazole with reference to CYP2C19 genotype Aliment Pharmacol Ther 43 1048-1059

[2] Sahara S(2011)Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]- J Pharmacol Exp Ther 339 412-420

[3] Ichikawa H(2015)-methylmethanamin e monofumarate (TAK-438) Clin Transl Gastroenterol. 6 e94-648

[4] Shin JM(2015)Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects Aliment Pharmacol Ther 41 636-541

[5] Inatomi N(2008)Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects Helicobacter. 13 532-8

[6] Munson K(2004)Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Basic Clin Pharmacol Toxicol 95 2-418

[7] Sakurai Y(2016) eradication: a meta-analysis Clin Pharmacokinet 55 409-1535

[8] Nishimura A(2016)CYP2C19 polymorphism and proton pump inhibitors Adv Ther. 33 1519-342

[9] Kennedy G(2002)The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations Clin Pharmacokinet 41 329-undefined

[10] Jenkins H(undefined)Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study undefined undefined undefined-undefined